| Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study K Sunami, H Ichikawa, T Kubo, M Kato, Y Fujiwara, A Shimomura, ... Cancer science 110 (4), 1480-1490, 2019 | 345 | 2019 |
| Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study S Pant, M Schuler, G Iyer, O Witt, T Doi, S Qin, J Tabernero, DA Reardon, ... The Lancet Oncology 24 (8), 925-935, 2023 | 85 | 2023 |
| First-in-human phase 1 study of morab-202, an antibody–drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-Α–positive advanced … T Shimizu, Y Fujiwara, K Yonemori, T Koyama, J Sato, K Tamura, ... Clinical Cancer Research 27 (14), 3905-3915, 2021 | 71 | 2021 |
| High frequency of neurolymphomatosis as a relapse disease of intravascular large B‐cell lymphoma K Matsue, BY Hayama, KI Iwama, T Koyama, H Fujiwara, M Yamakura, ... Cancer 117 (19), 4512-4521, 2011 | 60 | 2011 |
| Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors S Rottey, J Clarke, K Aung, JP Machiels, B Markman, KM Heinhuis, ... Clinical Cancer Research 28 (1), 95-105, 2022 | 42 | 2022 |
| Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study S Takahashi, Y Fujiwara, K Nakano, T Shimizu, J Tomomatsu, T Koyama, ... Cancer Science 112 (6), 2361-2370, 2021 | 41 | 2021 |
| Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer IT Nakamura, S Kohsaka, M Ikegami, H Ikeuchi, T Ueno, K Li, TS Beyett, ... npj Precision Oncology 5 (1), 66, 2021 | 40 | 2021 |
| Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety‐assessment cohort T Doi, Y Fujiwara, T Koyama, M Ikeda, C Helwig, M Watanabe, ... The oncologist 25 (9), e1292-e1302, 2020 | 40 | 2020 |
| The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan K Sunami, Y Naito, E Aimono, T Amano, D Ennishi, H Kage, M Kanai, ... International Journal of Clinical Oncology 26, 443-449, 2021 | 39 | 2021 |
| A rare case of high cervical spinal cord dural arteriovenous fistula presenting with intracranial subarachnoid hemorrhage H Ikeda, Y Fujimoto, T Koyama No shinkei geka. Neurological surgery 22 (11), 1045-1048, 1994 | 30 | 1994 |
| Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information R Hamamoto, T Koyama, N Kouno, T Yasuda, S Yui, K Sudo, M Hirata, ... Experimental hematology & oncology 11 (1), 82, 2022 | 28 | 2022 |
| 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study T Doi, M Patel, GS Falchook, T Koyama, CF Friedman, S Piha-Paul, ... Annals of Oncology 33, S744-S745, 2022 | 27 | 2022 |
| Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice H Ida, T Koyama, T Mizuno, K Sunami, T Kubo, K Sudo, K Tao, M Hirata, ... Cancer Science 113 (12), 4300-4310, 2022 | 25 | 2022 |
| Phase I study of the indoleamine 2, 3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients … T Ebata, T Shimizu, Y Fujiwara, K Tamura, S Kondo, S Iwasa, K Yonemori, ... Investigational New Drugs 38, 468-477, 2020 | 24 | 2020 |
| Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors T Shimizu, TE Nakajima, N Yamamoto, K Yonemori, T Koyama, S Kondo, ... Investigational New Drugs 40 (5), 1021-1031, 2022 | 23 | 2022 |
| Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review H Mizuta, E Nakano, A Takahashi, T Koyama, K Namikawa, N Yamazaki Dermatologic therapy 33 (3), e13321, 2020 | 23 | 2020 |
| Chronological improvement in precision oncology implementation in Japan K Sunami, Y Naito, K Komine, T Amano, D Ennishi, M Imai, H Kage, ... Cancer Science 113 (11), 3995-4000, 2022 | 22 | 2022 |
| First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors T Koyama, T Shimizu, S Iwasa, Y Fujiwara, S Kondo, S Kitano, ... Cancer Science 111 (2), 571-579, 2020 | 22 | 2020 |
| OA05. 05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study M Johnson, M Awad, T Koyama, M Gutierrez, GS Falchook, SA Piha-Paul, ... Journal of Thoracic Oncology 18 (11), S54-S55, 2023 | 20 | 2023 |
| A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors N Yamamoto, T Shimizu, K Yonemori, S Kitano, S Kondo, S Iwasa, ... Investigational New Drugs 39, 1036-1046, 2021 | 20 | 2021 |
